For research use only
| Cat No. | ABC-TC0045 |
| Product Type | Human Nerve Tumors Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Brain |
| Disease | Glioblastoma |
| Product Code | ANGMCSS |
ANGM-CSS human glioblastoma cell line from age 56 male shows fusiform morphology,adherent growth,forms cell heaps,positive for CD133,nestin,and vimentin.
ANGM-CSS is a human glioblastoma multiforme (GBM) cell line originally derived from the brain tissue of a 56-year-old male patient diagnosed with GBM. This permanent cell line displays a fusiform morphology and exhibits adherent growth characteristics in vitro, often forming multicellular aggregates. Immunohistochemical analysis has confirmed the expression of stemness and neural lineage markers, including CD133, nestin, and vimentin. Cytogenetically, ANGM-CSS exhibits a near-tetraploid karyotype, typically containing 88 to 91 chromosomes. It harbors multiple structural abnormalities, including unbalanced translocations such as t(6;14)(p12;q11. 2), t(8;10)(q24. 2;q21. 1), and t(5;9)(q34;p21). The cell line is tumorigenic and has been successfully propagated in animal models, making it a widely utilized preclinical model for evaluating novel therapeutic agents targeting glioblastoma.
| Product Code | ANGMCSS |
| Species | Human |
| Cat.No | ABC-TC0045 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Brain |
| Disease | Glioblastoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Nerve Tumors Cell Lines |
The ANGM-CSS cell line holds significant applications as a biologically relevant model for investigating the molecular pathology of glioblastoma multiforme. It proves valuable in evaluating the efficacy of novel therapeutic drugs in vitro. The cell line is instrumental in studying epigenetic alterations in gliomagenesis and identifying novel biomarkers for the diagnosis and therapeutic targeting of brain tumors. Moreover, it plays a crucial role in the development of effective strategies to induce differentiation and apoptosis in human glioblastoma multiforme cells, offering promising avenues for advancing research and potential treatments for this aggressive form of brain cancer.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
